ArticleWorld journal of gastroenterology2025
Growth differentiation factor 11 modulates metabolism, mitigating the pro-tumoral behavior provided by M2-like macrophages in hepatocellular carcinoma-derived cells.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Growth differentiation factor 11 reprograms M2-like macrophages: Targeting immunometabolism for cancer therapy.World journal of gastroenterology · 2026Article
- Kill two birds with one stone: Reprogramming tumor microenvironment with growth differentiation factor 11.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most aggressive tumors worldwide. Chronic inflammation contributes to tumor evolution, and the infiltration of tumor-associated macrophages (TAMs), also known as M2-like macrophages, is associated with the most aggressive behavior. Therefore, these macrophages provide the primary growth and migratory factors to the tumor cells, including those of HCC. Current therapies are not well optimized for eliminating transformed cells or neutralizing the tumor immune microenvironment leukocytes, such as TAMs. Growth differentiation factor 11 (GDF11) may represent a promising dual therapeutic target due to its reported anti-tumorigenic and immunomodulatory properties.
aimTo characterize the effects of GDF11 in M2-like macrophages and the HCC cell interaction using a functional
methodsThis research used THP-1 and Huh7 cell lines. We applied recombinant GDF11 (50 ng/mL) every 24 hours on THP-1 differentiated macrophages with M2-like polarization using interleukin-4 and interleukin-13. Firstly, the GDF11 effects on signaling, viability, proliferation, metabolism, and redox state in macrophages were characterized. Subsequently, we extracted conditioned media (CM) from macrophages and performed indirect co-cultures with Huh7 cells. The functional parameters were proliferation and migration assays. Finally, we characterized secretion in the CM using the cytokine array membrane assay.
resultsThe present study demonstrated that GDF11 activates the canonical pathway Smad2/3 without cytotoxic or proliferative effects. We provide evidence that GDF11 also diminishes the pro-tumoral properties of M2-like macrophages. GDF11 promoted the reduction of the M2-like macrophage marker, cluster of differentiation 206, indicating a loss of pro-tumoral properties in these leukocytes. Furthermore, this molecule induced changes in metabolism and an increase in reactive oxygen species. Using CM derived from GDF11-treated M2-like macrophages, we observed a reduction in the proliferation and migratory capacity of liver cancer cells. Moreover, the cytokine profile was affected by GDF11 stimulus, demonstrating that this molecule alters the pro-tumoral properties of TAMs, which in turn impact the behavior of HCC-derived cells.
conclusionThis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.